Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Clasificación en acciones #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Precio por acción
$150.78
Última sincronización: 2026-09-18
Capitalización bursátil
$187.20B
Cambio (1 día)
-0.08%
Cambio (1 año)
32.15%
País
US
Comercio Gilead Sciences, Inc. (GILD)

Categoría

EPS de Gilead Sciences, Inc. (GILD)
EPS a fecha de June 2026 TTM: $-2.60
Según los últimos informes financieros y el precio de las acciones de Gilead Sciences, Inc., el EPS actual de la empresa (TTM) es $-2.60. Al final del año 2024, la empresa tenía un EPS de $0.38 una disminución en comparación con al EPS de 2023, que fue de $4.54.
Historial de EPS de Gilead Sciences, Inc. desde 2000 hasta 2026
EPS al final de cada año
Año EPS Cambiar
2026 (TTM) $-2.60 -138.01%
2025 $6.84 1,700.00%
2024 $0.38 -91.63%
2023 $4.54 24.04%
2022 $3.66 -26.21%
2021 $4.96 4,966.39%
2020 $0.10 -97.69%
2019 $4.24 0.95%
2018 $4.20 18.64%
2017 $3.54 -64.88%
2016 $10.08 -18.51%
2015 $12.37 55.60%
2014 $7.95 295.52%
2013 $2.01 17.54%
2012 $1.71 -5.52%
2011 $1.81 6.47%
2010 $1.70 16.44%
2009 $1.46 33.94%
2008 $1.09 25.29%
2007 $0.87 -233.85%
2006 $-0.65 -244.44%
2005 $0.45 73.08%
2004 $0.26 -680.36%
2003 $-0.04 -196.76%
2002 $0.05 32.29%
2001 $0.04 -189.74%
2000 $-0.04 0.00%
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$29.85 -1,248.08%
US
$8.65 -432.69%
US
$3.55 -236.54%
US
$20.39 -884.19%
CH
$1.26 -148.46%
US